Clinical Observation on Effect of Toujie Quwen Granules in Treatment  of COVID-19

Xiao-xia FU; Lu-ping LIN; Xing-hua TAN

doi:10.13422/j.cnki.syfjx.20201314

您当前的位置：

首页 >

文章列表页 >

Clinical Observation on Effect of Toujie Quwen Granules in Treatment of COVID-19

Topic on Epidemic Resistance | 更新时间：2020-08-11

- Clinical Observation on Effect of Toujie Quwen Granules in Treatment of COVID-19
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 12, Pages: 44-48(2020)
- 作者机构：
  
  广州市第八人民医院，广州 510440
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20201314
  CLC： R285;R289;R22;R2-031
- Published Online：19 March 2020，
  
  Published：20 June 2020
- 稿件说明：
移动端阅览
傅晓霞,林路平,谭行华.透解祛瘟颗粒治疗新型冠状病毒肺炎临床观察[J].中国实验方剂学杂志,2020,26(12):44-48.

FU Xiao-xia,LIN Lu-ping,TAN Xing-hua.Clinical Observation on Effect of Toujie Quwen Granules in Treatment of COVID-19[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(12):44-48.
傅晓霞,林路平,谭行华.透解祛瘟颗粒治疗新型冠状病毒肺炎临床观察[J].中国实验方剂学杂志,2020,26(12):44-48. DOI： 10.13422/j.cnki.syfjx.20201314.

FU Xiao-xia,LIN Lu-ping,TAN Xing-hua.Clinical Observation on Effect of Toujie Quwen Granules in Treatment of COVID-19[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(12):44-48. DOI： 10.13422/j.cnki.syfjx.20201314.

摘要

目的

探讨透解祛瘟颗粒对新型冠状病毒肺炎患者早期疗效以及对相关外周血炎症指标表达影响。

方法

收集确诊轻型及普通型新型冠状病毒肺炎患者65例，分为治疗组32例，对照组33例，对照组口服阿比多尔，治疗组口服透解祛瘟颗粒。于治疗前后进行中医症状评分及外周血的白细胞计数（WBC），淋巴细胞计数（LYM），淋巴细胞比值（LYM%），中性粒细胞比值（NEU%），降钙素原（PCT），C反应蛋白（CRP），

D-

二聚体表达，胸部CT改善率等比较。

结果

治疗10 d后，治疗组患者中医症状积分明显减轻，总有效率高于对照组（

0.05），淋巴细胞计数上调，差异有统计学意义（

0.05）；组间分别比较，LYM计数，NEU%差异有统计学意义（

0.05）。WBC计数，LYM%差异无统计学意义。两组患者CRP，PCT，

D-

二聚体水平与治疗前比较均有显著下降（

0.05）。治疗后组间分别比较，CRP和PCT表达有显著差异（

0.05），

D-

二聚体表达差异无统计学意义。胸部CT改善程度两组无显著差异。

结论

早期及时使用透解祛瘟颗粒可以减轻新型冠状病毒肺炎患者的症状，调控相关外周血炎症指标的表达，有较好的临床疗效。

Abstract

Objective

To analyze the clinical efficacy of traditional Chinese medicine（TCM） Toujie Quwen granules in the treatment of coronavirs disease-2019（COVID-19） in the early stage

and its effect on relevant inflammatory index expression of COVID-19.

Method

A total of 65 COVID-19 cases were diagnosed and divided into 2 groups: the treatment group （

=32） and the control group （

=33）. Before and after treatment，TCM syndrome score，WBC，LYM，LYM%，NEU%，PCT，CRP and

D-

dimer were compared.

Result

After 10 days of treatment，the TCM syndrome score of the treatment group was significantly reduced（

0.05），while the absolute value of lymphocyte was up-regulated，with statistically significant differences（

0.05）， according to the inter-group comparison

there were statistically significant differences in the absolute value of LYM and NEU%（

0.05）. There was no significant difference in WBC count and LYM%. The levels of CRP，PCT and

D-

dimer in the two groups were reduced after treatment，with statistically significant differences between two groups （

0.05）. After treatment，the differences of CRP and PCT was statistically significant between both groups（

0.05），but the difference in

D-

dimer was not statistically significant. There was no difference in the effect of chest CT examination between the both groups.

Conclusion

The clinical syndrome and inflammatory particles of COVID-19 can be alleviated by early and timely use of Toujie Quwen granules.

关键词

Keywords

references

国家卫生健康委员会 . 世卫：新型冠状病毒感染的肺炎疫情构成国际关注的突发公共卫生事件 [ER/OL]. http://www.nhc.gov.cn/xcs/s3574/202002/3fdf885083e5470090728ede3c7f7e4b.shtml http://www.nhc.gov.cn/xcs/s3574/202002/3fdf885083e5470090728ede3c7f7e4b.shtml . 2020-01-31 / 2020-03-18 .

华中科技大学同济医学院附属同济医院救治医疗专家组 . 新型冠状病毒感染的肺炎诊疗快速指南（第三版） [J/OL]. 医药导报， 2020 ， doi： 42.1293.r.20200130.1803.002 http://dx.doi.org/42.1293.r.20200130.1803.002 .

ZHANG M M ， LIU X M ， HE L . Effect to integrated traditional Chinese and Western medicine on SARS: a review of clinical evidence ［J］． World J Gastroenterol ， 2004 ， 10 （ 23 ）: 3500 - 3505 .

LI J H ， WANG R Q ， GUO W J ， et al . Efficacy and safety of traditional Chinese medicine for the treatment of influenza A（HINI）:A meta-analysis ［J］． J Chin Med Assoc ， 2016 ， 79 （ 5 ）: 281 - 291 .

国家卫生健康委员会，国家中医药管理局 . 新型冠状病毒肺炎诊疗方案（试行第六版） .［EB/OL］． http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm/ http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm/ .2020-02-18/2020-02-26

夏文广，安长青，郑婵娟，等 . 中西医结合治疗新型冠状病毒肺炎34例临床研究 [J]. 中医杂志 2020 ， doi： 11.2166.R.20200217.1502.004 http://dx.doi.org/11.2166.R.20200217.1502.004 .

李素云，李高阳，张华茹，等．祛肺毒一号方治疗新型冠状病毒肺炎重型/危重型患者临床疗效分析 [J]. 中国实验方剂学杂志， 2020 ， doi： 10.13422/j.cnki.syfjx.20200843 http://dx.doi.org/10.13422/j.cnki.syfjx.20200843 .

王饶琼，杨思进，谢春光，等 . 清肺排毒汤治疗新型冠状病毒肺炎的临床疗效观察 [J]. 中药药理与临床， 2020 ， doi： 10.13412/j.cnki.zyyl.20200303.002 http://dx.doi.org/10.13412/j.cnki.zyyl.20200303.002 .

广州市卫生健康委员会 . 截至2020年2月23日24时广州市新冠肺炎疫情情况 [ER/OL]. http://www.gz.gov.cn/xw/jrgz/content/post_5673765.html http://www.gz.gov.cn/xw/jrgz/content/post_5673765.html . 2020-02-24 / 2020-03-18 .

广东省药品监督管理局，广东省卫生健康委员会，广东省中医药局 . 关于透解祛瘟颗粒（曾用名“肺炎1号方”）临床使用有关规定的通知［EB/OL］． http://mpa.gd.gov.cn/gkmlpt/content/2/2888/post_2888221.html/ http://mpa.gd.gov.cn/gkmlpt/content/2/2888/post_2888221.html/ ⁃2020⁃02⁃08⁃02⁃08

中华人民共和国卫生部 . 中药新药临床研究指导原则 [M]. 北京 : 中国医药科技出版社， 2002 : 186 .

中国研究型医院学会感染与炎症放射学专业委员会 . 新型冠状病毒肺炎影像学辅助诊断指南 [J]. 中国医学影像技术， 2020 ， 36 （ 3 ）: 1 - 11

王艳芳，陈建普，王翔，等 . 新型冠状病毒肺炎无症状感染者的CT影像分析 [J]. 武汉大学学报：医学版， doi： 10.14188/j.1671-8852.2020.0080 http://dx.doi.org/10.14188/j.1671-8852.2020.0080 .

HUANG C L ， WANG Y M ， LI X W ， et al . Clinical features of patients infected with 2019 novel coronavirus in Wuhan，China [J]. The Lancet ， doi: org.10.1016/S0140-6736（20）30183-5 http://dx.doi.org/org.10.1016/S0140-6736（20）30183-5 .

林立伟，陈湘平，黄浩，等 . 降钙素原、 D- 二聚体、C反应蛋白及胆碱酯酶对重症肺炎患者病情及预后的评估价值 [J]. 临床合理用药杂志， 2018 ， 11 （ 8 ）: 150 - 151 .

董双霞，潘林艳，金海珍，等 . 重症肺炎中超敏C反应蛋白及 D- 二聚体早期诊疗价值及预后影响因素分析 [J]. 中国药物与临床， 2019 ， 19 （ 12 ）: 2035 - 2037 .

姬广海，黄满华，张庆，等 . 新型冠状病毒肺炎CT表现及动态变化 [J]. 中国医学影像技术， 2020 ， 36 （ 2 ）: 242 - 247 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Effect of Xiaozhi Hugan Capsules in Treatment of Patients with Non-alcoholic Steatohepatitis and Its Impact on Serum IL-6 and MCP-1

Immunomodulatory Effect of Shufeng Jiedu Capsules and Active Components in Treating Respiratory Tract Infections： A Review

Bidirectional Mendelian Randomization Analysis of Causal Relationship Between Constipation and Pneumonia

Clinical Efficacy and Safety of Qingyusan Capsules in Treatment of Ulcerative Colitis with Syndrome of Large Intestine Dampness-heat

Qianjin Weijingtang in Treatment of Chronic Obstructive Pulmonary Disease： A Review

Related Author

LIU Xiaoyan

MA Suping

MA Qingliang

LI Chunxiao

ZHANG Lihui

CHEN Huaxin

ZHAO Wenxia

BAO Lei

Related Institution

The First Clinical Medical College， Henan University of Chinese Medicine

The First Affiliated Hospital of Henan University of Chinese Medicine

Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences

State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs， Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences

The Third Affiliated Hospital of Beijing University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰